Verana Health®

DATASHEET
Myelodysplastic Syndrome

Qdata® Myelodysplastic Syndrome is an exclusive dataset providing a longitudinal view of diagnosis, risk classification, treatment patterns, and real-world outcomes in real-world clinical practice.

Verana Health® powers oncology research with high-quality real-world data sourced from curated electronic health records and linked data sources at leading cancer centers across the US. Built specifically for cancer research, Verana Health's oncology datasets and analytics deliver clinically rich insights across tumor types and lines of therapy, supporting evidence generation at every stage of the drug development and commercialization lifecycle.

Abstracted Data

ABSTRACTED	ACCESSIBLE	ABSTRACTED + ACCESSIBLE
6,080	17,700+	23,780+

Potential patients as of Q3 2026

Note: Abstracted data is available for immediate delivery. Accessible data requires additional curation.

Clinician-led and AI-enabled oncology data platform

Verana Health securely ingests, links, and curates raw oncology care data from point-of-care clinical encounters. Purpose-built, fit-for-purpose data is designed to support rigorous research and confident decision-making across the oncology lifecycle.

Ingest Data
Structured and unstructured oncology EHR data are captured and de-identified, preserving clinical nuance from real-world care delivery.

Link Data
Data are harmonized and tokenized across EHR systems and linked with complementary sources, including claims data, biomarker and genomic data, and other relevant clinical inputs.

Curate Data
Data are clinically abstracted, quality-controlled, and continuously curated using expert oncology oversight and technology.

Curated, High-Quality Oncology Data

Available across multiple tumor types and treatment settings, including:

Hematologic cancers:
- Acute Lymphoblastic Leukemia
- Acute Myeloid Leukemia
- Chronic Lymphocytic Leukemia
- Diffuse Large B Cell Lymphoma
- Follicular Lymphoma
- Marginal Zone Lymphoma
- Multiple Myeloma
- Myelodysplastic Syndrome
- Small Lymphocytic Lymphoma
- Mantle Cell Lymphoma

Solid tumor cancers:
- Breast Cancer
- Colon Cancer
- Rectal Cancer
- Gastric Cancer
- Lung Cancer
- Melanoma
- Ovarian Cancer
- Pancreatic Cancer
- Prostate Cancer

Verana Health®

DATASHEET
Myelodysplastic Syndrome

Abstracted Data Summary:

DATA SET QUALITY

2.8 yrs	Average length of follow-up
20.6	Performance statuses on avg. per patient
81%	patients with performance status
13%	of MDS patients transformed to AML
94%	Patients with race data
88%	Patients with ethnicity data
34%	Patients with outcome data

RISK GROUPS

Low	1,731
Intermediate	1,597
High	722
Very High	249

TREATMENT HIGHLIGHTS

Venetoclax	310
Hypomethylating Agents	2,601

1,456 Relapse/ Refractory — Total 6,080

About Verana Health

Verana Health, Inc.® is a digital health company revolutionizing patient care and clinical research by utilizing physician expertise and artificial intelligence to unlock the true potential of real-world data. With exclusive access to the world's largest patient data sources in oncology, ophthalmology, neurology, and urology. Verana Health is powering real-world evidence generation. Clinicians utilize these insights to improve the quality of care and quality of life for patients, and life sciences companies rely on the insights to accelerate the development of new therapies. For more information, visit www.veranahealth.com.

© 2026 Verana Health | Datasheet | Myelodysplastic Syndrome | October 2026